X T L Biopharmaceuticals reported $881.39M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.





Ordinary Share Capital Change Date
Alaunos Therapeutics USD 2.38M 172K Mar/2026
Bioline Rx USD 2.61B 0 Dec/2025
Teva Pharmaceutical Industries USD 1.16B 16.72M Mar/2026
X T L Biopharmaceuticals USD 881.39M 858.25M Jun/2025